Natrecor Phase IV Study Should Assess Drug In Acute MI, Cmte. Says
Executive Summary
Scios' Natrecor should be assessed in patients with acute myocardial infarction in Phase IV studies, members of FDA's Cardiovascular & Renal Drugs Advisory Committee suggested Jan. 29.